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In recent years, the imbalance in phosphate homeostasis in patients with end-stage renal disease (ESRD) has been
the subject of much research. It appears that, while hyperphosphatemia may be a tangible indicator of
deteriorating kidney function, lack of phosphate homeostasis may also be associated with the increased risk of
cardiovascular events and mortality that has become a hallmark of ESRD. The need to maintain phosphorus
concentrations within a recommended range is reflected in evidence-based guidelines. However, these do not
reflect serum phosphorus concentrations achieved by most patients in clinical practice. Given this discrepancy, it is
important to consider ways in which dietary restriction of phosphorus intake and, in particular, use of phosphate
binders in patients with ESRD can be made more effective. Poor adherence is common in patients with ESRD and
has been associated with inadequate control of serum phosphorus concentrations. Studies indicate that, among
other factors, major reasons for poor adherence to phosphate binder therapy include high pill burden and patients’
lack of understanding of their condition and its treatment. This review examines available evidence, seeking to
understand fully the reasons underlying poor adherence in patients with ESRD and consider possible strategies for
improving adherence in clinical practice.
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Hyperphosphatemia and outcomes in ESRD
Among patients with end-stage renal disease (ESRD),
progressive deterioration of kidney function results in el-
evated phosphorus concentrations in tissue and in serum
[1]. This has been associated with a number of clinical
complications. In particular, the link between dysregu-
lated phosphate homeostasis and increased mortality
and morbidity has been demonstrated in a number of
studies. For example, assessment of data from 40,538
hemodialysis patients in adjusted models revealed a step-
wise increase in the relative risk of mortality associated
with increasing serum phosphorus concentrations above
5 mg/dL [2]. In the retrospective United States (US)
Renal Data System Waves 1, 3 and 4 study, which in-
cluded 14,829 patients on hemodialysis, an association* Correspondence: accovic@gmail.com
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distribution, and reproduction in any mediumbetween phosphorus concentrations and the primary
outcome of first cardiovascular (CV) events was obser-
ved from phosphorus concentrations of 4.5–5.3 mg/dL.
Phosphorus concentrations of above 6.4 mg/dL were
associated with an increased risk of all-cause morta-
lity [3]. In addition, prospectively collected data from
a 2-year historic cohort of 58,058 patients on mainten-
ance hemodialysis showed that hyperphosphatemia (over
6 mg/dL) was consistently associated with increased risk
of death [4].
These studies are among 27 studies that examined the
relationship between dysregulated mineral metabolism
and all-cause or CV mortality or CV events in patients
with chronic kidney disease (CKD) or ESRD that were
included in a systematic review. Although the authors
noted limitations in the analysis owing to the low num-
ber of studies included and the quality of the data
obtained from them, a greater risk of all-cause mortality
was seen with elevated phosphorus concentrations: all
but one of the 17 studies assessing these factors reportedntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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nificantly higher risk of CV mortality was reported with
high phosphorus concentrations [5].
Other studies that were published too late to be in-
cluded in the systematic review support its conclusions.
These included the Dialysis Outcomes and Practice
Patterns Study (DOPPS), a prospective cohort study in
25,588 patients with end-stage kidney disease on hemo-
dialysis, reported an increased risk of CV mortality with
serum phosphorus concentrations of 5.1–5.5 mg/dL, and
an increase in all-cause mortality at serum phosphorus
concentrations over 6.0 mg/dL [6]. In another pros-
pective cohort of 10,044 patients who were beginning
hemodialysis, serum phosphorus concentrations of grea-
ter than 5.5 mg/dL were associated with an increased
risk of death compared with phosphorus concentrations
of 3.5–4.5 mg/dL [7]. Results from a European study in-
cluding 7,970 hemodialysis patients showed that those
whose serum phosphorus concentrations were either
above or below the National Kidney Foundation Disease
Outcomes Quality Initiative (KDOQI)-recommended
range had a significantly increased risk of mortality [8].
Establishing a threshold level of serum phosphorus
load at which the risk of all-cause or CV mortality in-
creases significantly will be critical for optimizing care
strategies [5]. The need for control of serum phosphorus
concentrations is reflected in the evidence-based Kid-
ney Disease: Improving Global Outcomes (KDIGO) and
KDOQI guidelines. These recommend the use of phos-
phate binders if serum phosphorus concentrations exceed
those within the guideline ranges (toward the normal
range for patients with Stage 5D CKD and 3.5–5.5 mg/dL
for patients with Stage 5 CKD, respectively) [9,10]. How-
ever, it should be noted that no phosphate binder has been
approved by the US Food and Drug Administration (FDA)
for patients not on dialysis.
Despite publication of these guidelines, there is a gap
between the recommendations and serum phosphorus
concentrations achieved by the majority of patients in
clinical practice [11]. For example, only 44% of patients
in DOPPS II achieved serum phosphorus concentrations
within the recommended range [12]. Precise reasons for
this gap remain unclear and likely contributing factors
will be examined further in this review.
Seeking to control hyperphosphatemia and improve
outcomes: use of phosphate binders
Treatment of the majority of patients with ESRD often
necessitates a multimodal approach, comprising dialysis,
dietary restriction of phosphorus intake and use of phos-
phate binders.
Dietary restriction of phosphorus intake has an im-
portant role in the management of serum phosphorus
load, as evidenced by the finding that higher levels ofdietary phosphorus intake and higher dietary phos-
phorus to protein ratios correlated with greater 5-year
mortality in hemodialysis patients [13]. Educating pa-
tients to avoid major sources of natural phosphorus
(often protein-rich foods) and phosphorus-containing
additives (e.g., those found in soft drinks and processed
meat), and to prepare phosphorus-rich foods by boiling
to reduce phosphorus content, contributes to their
serum phosphorus control [14]. Absorption of phos-
phorus via the gastrointestinal tract varies with food
source, being lower for plant-based materials that in-
clude phytate and higher for foods enhanced with inor-
ganic phosphorus-containing preservatives [14].
However, the balance between maintaining sufficient
protein intake and restricting phosphorus intake, and ef-
fect on clinical outcomes, can be complex. It is recom-
mended that dietary protein intake in clinically stable
dialysis patients should be at least 1.1 g protein/kg ideal
body weight/day [15]. However, higher protein intake
(up to 1.4 g/kg/day, based on normalized protein ni-
trogen appearance) has been associated with increased
survival in one study, despite an associated increase in
serum phosphorus [16]. An additional consideration is
that dialysis patients may be more prone to malnutrition
resulting from a low-protein diet and/or lack of appetite
[17]. Indeed, one post hoc analysis carried out on data
from 1,751 hemodialysis patients found that prescribed
dietary phosphorus restriction was not associated with
survival benefit [18]. As such, there has been much de-
bate about the potential benefits and risks of limiting
dietary phosphorus intake in dialysis patients [16,17].
Furthermore, dietary phosphorus restriction may be asso-
ciated with longer-term impracticalities and is often insuf-
ficient to maintain phosphate control [19]. This problem
is exacerbated by the fact that, in addition to foods natur-
ally rich in phosphate, phosphate additives are commonly
found in processed foods that may not always be labeled
accordingly but contain a high, often ‘hidden’, phosphate
load [20,21]. This makes restriction of phosphate intake
increasingly challenging for patients.
A typical phosphorus-restricted diet for hemodialysis
patients includes ~900 mg of phosphorus per day, of
which ~371 mg are absorbed [22]. Therefore, additional
means of reducing serum phosphorus load are necessi-
tated, and most patients require the use of phosphate
binders [23]. Phosphate binders can provide the patient
with greater nutritional freedom. However, different
types of binders have different phosphate binding cap-
acities; for example, in one study, lanthanum carbonate
bound 135 mg phosphate per tablet, whereas sevelamer
carbonate bound 21 mg phosphate per tablet [24]. Dif-
ferent phosphate binders are, therefore, associated with
varying pill burden (Table 1) [25-31]. A potential means
of reducing pill burden would be if patients were to
Table 1 Overview of currently available phosphate binders [27,28,30,31,35-37]
Phosphate
binder
Mechanism of action Typical daily pill
burden*
Advantages Disadvantages
Aluminum salts Aluminum binds to phosphates
and forms insoluble precipitate in
GI tract; aluminum hydroxide also
forms compounds with
phosphate ions in the blood
No safe dose identified Effective, inexpensive Associated with cognitive
disturbances, osteomalacia and




Dissociation in GI tract; calcium
binds to phosphates and forms
insoluble precipitate
4–6 pills (1000 mg each,
equivalent to 250 mg
calcium) per day
Effective and inexpensive Potential for increased
hypercalcemia; could lead to




Dissociation in GI tract; calcium
binds to phosphates and forms
insoluble precipitate
Pill number as prescribed
per day (1250 mg each,
equivalent to 500 mg calcium)
Effective and inexpensive Potential for increased
hypercalcemia; could lead to





Dissociation of the active
compounds calcium acetate and
magnesium carbonate in the GI
tract; each binds to phosphate
and forms insoluble precipitate
Total: 3–10 pills per day
(each pill contains







Monitoring of magnesium level
required; in some
circumstances, moderate
increase in serum magnesium
level
Sevelamer HCl Anion exchange resin that
exchanges chloride ions for
phosphate ions






Expensive; high pill burden;
associated with GI side effects






Anion exchange resin that
exchanges chloride ions for
phosphate ions






available as a powder,
which may reduce pill
burden
Expensive; high pill burden;
associated with GI side effects
Lanthanum
carbonate
Dissociation in the upper GI tract;
lanthanum then binds to
phosphates and forms insoluble,
non-absorbable lanthanum
phosphate complexes
1 pill (500 mg, 750 mg
or 1000 mg) three times
daily (Total: 3 pills/day)
Effective, low pill burden Expensive; associated with GI
side effects such as nausea,
vomiting
GI = gastrointestinal, HCl = hydrochloride.
*Timing and dose of phosphate binder to be adjusted in line with timing of meals/snacks and the phosphorus content thereof.
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phosphorus content of each meal or snack [14]. It is im-
portant to note that the benefits of phosphate binder
treatment should ideally extend beyond biochemical or
laboratory parameters (such as serum phosphorus con-
centrations) to hard clinical outcomes such as CV events
or prolonged survival. There are few placebo-controlled
interventional studies examining the effect of phosphate
binder treatment on survival. However, data from obser-
vational studies have accumulated that support the view
that early treatment with phosphate binders is associated
with prolonged survival [32-34]. For example, a pro-
spective cohort study compared the 1-year mortality rate
of patients initiating outpatient hemodialysis who were
treated with phosphate binders during the first 90 days
(n = 3,555) with that of patients who did not receive
treatment with phosphate binders (n = 5,055). Patients
treated with phosphate binders had a significantly lo-
wer mortality rate compared with untreated patients(multivariable-adjusted hazard ratio [HR] in the in-
tention-to-treat analysis: 0.70; 95% confidence interval
[CI]: 0.62–0.79; p < 0.0001) [32]. Treatment with phos-
phate binders was independently associated with de-
creased mortality compared with no treatment in the
intention-to-treat and the as-treated analyses, with the
magnitude of benefit ranging from 18–30% [32]. In an-
other study including 23,898 patients on maintenance
hemodialysis, those who were prescribed phosphate
binders (n = 21,061) exhibited 25% lower mortality (HR:
0.75; 95% CI: 0.68–0.83) in models adjusted for covari-
ates including serum phosphorus, but not adjusted for
nutritional factors. Adjusting for nutritional factors
somewhat reduced the strength of the association be-
tween phosphate binder treatment and lower mortality
(HR: 0.88; 95% CI: 0.80–0.97). Of note, in this study, pa-
tients treated with phosphate binders had a lower mor-
tality rate, but this may have been partly explained by
better nutritional status in these patients compared with
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[34].
Overall, there is a lack of long-term data from ran-
domized, controlled studies evaluating the relative effi-
cacy of specific phosphate binders on hard clinical
outcomes such as mortality and musculoskeletal mor-
bidity [29,38]. Furthermore, available data have been
somewhat contradictory. Results of the randomized,
open-label Dialysis Clinical Outcomes Revisited study in
2,103 hemodialysis patients showed no difference in the
primary endpoint of all-cause mortality among patients
receiving sevelamer hydrochloride (HCl) compared with
those receiving a calcium-based phosphate binder, al-
though a significantly lower risk of mortality was repor-
ted in patients ≥65 years receiving sevelamer compared
with those receiving a calcium-based binder (p = 0.02)
[39]. These data contrast with results from the random-
ized, open-label Renagel In New Dialysis study in 148
patients new to hemodialysis who were randomized to
receive calcium-based phosphate binders or sevelamer
HCl. In this study, the 18-month coronary artery calcifi-
cation score increased significantly in each treatment
group but was significantly larger with calcium-based
binders than with sevelamer (p = 0.01) [40]. After a me-
dian follow-up of 44 months, mortality was significantly
higher in patients receiving calcium-based binders than
in those receiving sevelamer (p = 0.05) [41]. In line with
these observations, the prospective, randomized Treat
To Goal study in 200 hemodialysis patients reported
no significant differences in serum phosphorus and cal-
cium × phosphorus product between patients receiving
calcium-based phosphate binders and those receiving
sevelamer HCl from baseline to 52 weeks. However,
patients receiving a calcium-based binder showed signifi-
cant progression in coronary artery and aortic calcifica-
tion at Week 52, whereas those receiving sevelamer HCl
showed no significant change in these parameters [42].
Results such as these have prompted concerns that the
combined long-term effects of dysregulated mineral me-
tabolism and its treatment with calcium-based phos-
phate binders may contribute to calcium overload and
vascular calcification [43]. Results from a recently pub-
lished pilot clinical trial in 148 patients with moderate
CKD and near-to-normal serum phosphorus concentra-
tions have not clarified this matter. These data reiterated
the efficacy of phosphate binders in reducing serum
phosphorus concentrations, but showed progression of
arterial calcification with phosphate binder treatment in
these patients compared with placebo. The apparent ad-
verse effects on vascular calcification were more pro-
nounced among patients randomized to calcium acetate,
although patient numbers were low in this subset ana-
lysis [44]. It should be emphasized that the patient
population selected for this study was different to thosein previous studies in this area. Until these datasets can
be fully explained, the role of the phosphate binders –
and specifically different types of phosphate binders – in
changing outcomes, in patients with CKD who have not
yet progressed to ESRD and in patients with ESRD, will
remain a focus of future research.
Currently available phosphate binders differ in their
overall effectiveness in the short and long term, their
mode of action, composition and tolerability [22]. A
number of factors may contribute to the differences in
effectiveness between currently available phosphate bin-
ders, one of which is poor adherence.Lack of treatment adherence: a problem of chronic
illnesses or specific to ESRD?
Poor adherence to prescribed drug therapy is a well-
established obstacle to treatment success, with efforts to
improve it hampered further by a lack of consistency in
defining and measuring adherence across existing stud-
ies [45]. One meta-analysis of 21 studies including
46,847 patients with various conditions such as recent
myocardial infarction, HIV and type 2 diabetes showed
that patients with good adherence to drug therapy had a
significantly reduced risk of mortality compared with pa-
tients whose adherence was poor (pooled odds ratio:
0.56; 95% CI: 0.50–0.63). Interestingly, this effect ex-
tended to those who were adherent to placebo [46].
It appears that poor adherence is common in ESRD,
and its detrimental impact on patients has been noted:
missing hemodialysis treatments has been associated
with an increased risk of mortality [47] and poor adher-
ence to phosphate binder therapy has been associated
with failure to adequately control serum phosphorus
concentrations [48]. In one study, treatment adherence
to phosphate binders was assessed using questionnaires
in 165 hemodialysis patients. Of these, 40% were found
to be non-adherent to their overall medication regimen
and 21% specified that they were non-compliant with
their phosphate binder regimen. Patients who did not
take their phosphate binders were significantly more
likely to exhibit mean serum phosphorus concentra-
tions >5.5 mg/dL (X2 = 4.7; 95% CI: 1.07–6.5; p = 0.03)
[48]. Overall, reported rates of non-adherence to phos-
phate binders vary widely across studies, from 21% to
74% [48-50]. This wide range could be attributed to dif-
ferences in the definition of non-adherence between
studies [45]. In addition, methodologies may differ be-
tween studies, contributing to variation in the data. For
example, direct monitoring methods include drug con-
centration assays, use of pill markers and direct obser-
vation of pill taking; indirect methods include patient
self-reports, compliance ratings by nurses, prescription re-
fills, pill counts and microelectronic monitoring devices.
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patients [45].
It has been suggested that the efficacy demonstrated
by phosphate binders in clinical trials, considered to-
gether with the fact that many patients using phosphate
binders have serum phosphorus concentrations outside
the KDOQI-recommended range, indicate that the ef-
fectiveness of current phosphate binders is compromised
by poor adherence [25]. Indeed, it has been noted that
patient expectations, preference and adherence are at
least as important as the efficacy of the prescribed phos-
phate binder [27]. In general, adherence levels are lowest
in patients with chronic disease who perceive no imme-
diate symptoms or risk if they do not take their medica-
tion, and are required to change their lifestyle in order
to adhere to their prescribed treatment program [48].
Patients on dialysis fall into this category [48]. However,
relatively few data are available to help us to understand
other, more specific, reasons why hemodialysis patients
show poor adherence to phosphate binder therapy.
Available studies indicate that patients’ lack of under-
standing of their condition and treatment plays a role
[11]. Other factors may include the cost of treatment
and the possibility that physicians may prescribe increas-
ingly high doses of phosphate binders to improve poor
efficacy that may in fact be due to poor adherence.
Lastly, a major reason for poor adherence is often cited
as the high pill burden associated with currently avail-
able phosphate binders [49]. These are discussed in turn
below.
Treatment adherence and phosphate binders: unraveling
the effect of pill burden
Dialysis patients are required to take a large number of
medications. These are needed not only to control hy-
perphosphatemia, but also to manage a number of other
conditions such as diabetes or hypertension. The im-
portance of reducing pill burden and simplifying re-
gimens to improve adherence has been highlighted in
other diseases, such as HIV [51] and CV disease [52]. In
ESRD, the complexity of combined treatment regimens
presents a challenge for both prescribers and patients
[45]. A study assessing the medication prescribing pat-
terns for 10,474 ambulatory hemodialysis patients in the
Dialysis Clinic, Inc. database revealed that the number
of medications being prescribed is increasing, with a
mean of 12.3 ± 5 different medications being used by
each patient [53]. Of these patients, 88% were using
phosphate binders [53].
Results from a study of 233 patients on maintenance
dialysis from three different units in the US showed that
patients took a mean of 11 ± 4 medications (nine oral,
two parenteral), with a median daily pill intake of 19
(inter-quartile range [IQR]: 12) [49]. Phosphate bindersaccounted for 49 ± 19% of the total pill burden, with a
median pill count of 9 (IQR: 6) [49]. Only 38% of pa-
tients in this study were adherent to their prescribed
phosphate binder therapy (taking 80–120% of expected
pill count), and adherence decreased significantly with in-
creased pill count (r = −0.19; p = 0.006). Importantly, me-
dian serum phosphorus concentrations were 5.2 mg/dL
(IQR: 1.4) [49]. Furthermore, multivariate analyses showed
that a high total pill burden was independently associated
with low physical component summary scores of the
short-form (SF)-36 quality of life assessment, although no
relationship was observed between the mental component
of SF-36 and pill burden [49].
In summary, a higher phosphate binder pill burden
has been associated with lower adherence and higher
serum phosphorus concentrations [48,49]. Further inves-
tigation to establish the relative impact of frequency of
administration and reduction in pill number taken at
each administration would be of interest and could
further guide clinical decisions. Furthermore, alternative
formulations of phosphate binders, such as powder for-
mulations, have the potential to reduce pill burden and
further support adherence [54,55]. In the meantime,
efforts to reduce the pill burden associated with phos-
phate binders should continue in an effort to improve
adherence.
Treatment adherence is multifactorial
As with treatment of many chronic diseases, patient so-
cioeconomic status, education and demographics can
affect adherence. An important factor is patient age. Al-
though it has been reported that older patients (>65
years) tend to be more adherent to treatment [45], the
high prevalence of cognitive impairment among the
hemodialysis population, in particular during dialysis it-
self (when many conversations about medication take
place), may lead to confusion about complex medication
regimens [56].
In a study of 188 dialysis patients, 129 of which were
receiving hemodialysis, the primary reason given by pa-
tients for their non-adherence was being unaware of the
correct prescription (37%). This was followed by patients
forgetting their pills (30%). Interestingly, patients who
admitted to poor adherence were prescribed more phos-
phate binders, and took fewer of them, than their adher-
ent counterparts [57]. This indicates that as patients do
not always report their non-adherence, their physicians
may increase the prescribed dose in an attempt to re-
establish phosphate control, initiating a cycle of increa-
ses in pill burden and attendant reduction in adherence.
In support of this, another study reported that patients
who admit to being non-adherent and exhibit higher
phosphorus concentrations are being prescribed the
highest doses of binders [48].
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standing of hyperphosphatemia, its management and its
potentially detrimental impact on their health may affect
adherence [45]. Hyperphosphatemia, like many other
chronic diseases including hypertension, dyslipidemia
and osteoporosis, is a silent condition until the mani-
festation of potentially fatal symptoms. This disconnect
between the potential severity of the condition and pa-
tients’ understanding of its impact on their health could
be addressed with tailored education initiatives.
Lastly, existing phosphate binders are associated with
different adverse effect profiles (Table 1), which should
be considered in tandem with their clinical efficacy and,
together with pill burden, may affect phosphate binder
choice or patient satisfaction. This highlights the impor-
tance of offering a wider choice of medication, enabling
physicians to customize treatment to the needs of indi-
vidual patients.
How can we improve adherence in patients with ESRD?
Interventions to improve treatment adherence in the long
term often comprise multiple components including im-
proved education, reminders, self-monitoring, telephone
follow-up and supportive care. Despite this, approaches in
chronic disease have often had limited effect [58]. For pa-
tients with ESRD, a number of strategies could be investi-
gated (or investigated further; Table 2). Of these, patient
education is likely to play an important role in improving
adherence in ESRD, and, with it, control of serum phos-
phorus concentrations. Some examples of successful patient
education programs have been published. For example, in a
randomized, parallel-group, controlled study including 56Table 2 Potential strategies to improve control ofdietary pho
patients with ESRD
Patient education
• Introduce education pro
focusing on the:
◦ Physiologic role of p
◦ Role of phosphate in
◦ Importance of phosp
◦ Importance of dietar
• Involve patients’ families
• Tailor education to patie
socioeconomic status
• Educate patients on app
Patient empowerment
• Introduce initiatives such
hyperphosphatemia to e
binder dose accordingly
Improve properties of phosphate binders
• Reduce pill size and burd
• Improve palatability
• Reduce associated adver
• Introduce electronic mon
medication and supporthemodialysis patients, those who attended an education
session about phosphate management showed a significant
reduction in serum phosphorus concentrations after at-
tending. This was maintained up to 3 months, whereas no
significant change in serum phosphorus concentrations was
observed in the control group [59]. Similarly, 34 patients
with stage 4–5 CKD, most of whom were on hemodialysis,
who attended a 2-month structured educational program
as part of a smaller, non-randomized study exhibited sig-
nificantly reduced plasma phosphate up to 12 months [60].
Finally, in a study of a nurse-led intervention, 41
hemodialysis patients attended an education session about
phosphate binders 5 weeks into the study period, followed
by bi-weekly personalized counseling sessions until Week
17 (end of study). Adherence to phosphate binders in-
creased from 83% to 94% over the study period, compared
with a reduction from 86% to 76% in historic controls. This
was matched by a reduction in serum phosphorus concen-
trations from 4.9 to 4.3 mg/dL in patients on the study
[61]. Again, lessons can be learned from the long-term
treatment of other conditions: a pharmacy care program in-
cluding education initiatives and custom-packaged medica-
tion led to a significant and sustained improvement in
adherence after 14 months in patients taking at least four
daily medications for chronic conditions [62]. Initiatives
such as this may require greater coordination of care and
sharing of patient data between different care settings [63].
The success of patient education initiatives relies to
some extent on patients themselves being fully engaged
with their treatment. Patients have to contend with the
fact that dietary phosphorus content has been shown to
vary substantially depending on the type of meal [64],sphorus intake and adherence to phosphate binders in
grams, led by nurses or other ancillary healthcare providers,
hosphate and its presence in different foods
ESRD-associated cardiovascular disease
hate binders and their role in lowering serum phosphorusconcentrations
y adherence
and friends in education initiatives
nt’s lifestyle, environment, career, ethnicity, cultural background and
ropriate food choices and provide training on preparing suitable meals
as the ‘Phosphate Education Program’ that enable patients with
stimate the phosphate content of their meals and adjust their phosphate
en
se effects
itoring devices, which may help patients to remember to take their
adherence
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larly under-, dosing [64]. Empowered patients can apply
knowledge about their treatment to adopt a suitably
flexible approach, for example to counteract potential
shortcomings in a typical fixed-dose phosphate binder
regimen by adapting the timing and level of their phos-
phate binder intake on a meal-by-meal basis [64]. A pro-
spective study which may serve as an example of this
approach was based on patient empowerment and family
support. Parents of children with various stages of CKD
(pre-dialysis and on dialysis) estimated the inorganic
phosphorus content of meals and adjusted phosphate
binder dosage accordingly at each meal time. Mean se-
rum phosphorus concentrations decreased significantly
up to 12 weeks after the initial workshop. The study also
showed a relatively high rate of patient adherence to the
program (median 8.0 on a scale of 1–10), increased
phosphate binder consumption and increased patient
satisfaction at meal times [65]. The approach used in
this study was the Phosphate Education Program (PEP),
which applies the concept of a ‘Phosphorus Unit’ to indi-
cate the phosphorus content of food groups, allowing
patients to quickly estimate the phosphorus content of
their meals without referring to complex tables or cal-
culations, and to adjust their phosphate binder intake
accordingly [64]. As such, the PEP represents a novel ap-
proach, integrating patient empowerment into the ma-
nagement of hyperphosphatemia [64].
Simplification of dosing regimens by reducing pill
burden and size, and improving the palatability of phos-
phate binders is also likely to improve patient satis-
faction and, with it, adherence. For example, calcium
acetate gelcaps are easier to swallow than tablets and are
reportedly preferred by patients [66]. Patient and phys-
ician preference data have also been reported in one
study that compared lanthanum carbonate with patients’
previous phosphate binders. One of the principal reasons
for patients’ stated preference for lanthanum carbonate
was ‘number of tablets’ [67].
Currently, few randomized, controlled studies provide
an insight into differences in adherence between phos-
phate binders. Given the considerations above, it has
been stated that an ideal phosphate binder should be as-
sociated with few adverse effects; have high efficacy re-
gardless of pH, good palatability and no or minimal
absorption in the digestive tract; require low daily do-
sing; and be available at a low cost [68]. Until this ideal
is met, treatment tailored to the individual patient and
their circumstances is required.
Conclusions
In order for us to update guidelines and optimize patient
care, some gaps in the evidence base need to be addressed.
Although available data demonstrate the associationbetween hyperphosphatemia and increased risk of mor-
tality, it remains a challenge in the clinic to achieve and
maintain recommended serum phosphorus concen-
trations. A major obstacle to doing so is the problem
of patient adherence to diet and phosphate binders.
We suggest that an approach to improve patient ad-
herence should comprise three components: firstly,
standardization of methods for measuring and monitoring
adherence between studies in ESRD; second, scientific
validation of strategies to improve adherence, such as pa-
tient reminders and comprehensive patient education; and
lastly, continued clinical research into development of
new formulations and/or phosphate binders with a re-
duced pill burden.
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